Clinical Trials Logo

Advanced Epithelioid Sarcoma clinical trials

View clinical trials related to Advanced Epithelioid Sarcoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04204941 Recruiting - Clinical trials for Advanced Soft-tissue Sarcoma

Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Start date: December 19, 2019
Phase: Phase 3
Study type: Interventional

The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse. The study drug is called tazemetostat. The study will test tazemetostat in combination with doxorubicin compared to placebo (dummy treatment) in combination with doxorubicin. Doxorubicin is a current front line treatment for epithelioid sarcoma